Zynyz Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing cancer incidence rates, limitations of conventional chemotherapy, expansion of molecular oncology research, improved understanding of cancer cell signaling pathways, rising clinical trials for kinase inhibitors.

The growth in the forecast period can be attributed to increasing development of next-generation kinase inhibitors, rising demand for precision oncology treatments, expansion of targeted cancer drug pipelines, growing investments in molecular cancer therapies, increasing adoption of biomarker-driven treatments. Major trends in the forecast period include increasing adoption of targeted kinase inhibitors, rising focus on cell cycle modulation therapies, growing use of precision oncology approaches, expansion of targeted small molecule drugs, enhanced emphasis on cancer growth suppression.

The rising cancer rates are expected to drive the growth of the Zynyz market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The increasing cancer rates can be attributed to factors such as an aging population, unhealthy lifestyle choices, environmental exposures, genetic predispositions, improved detection methods, infections, obesity, and hormonal changes. Zynyz helps manage cancer by enhancing the immune system’s ability to recognize and attack cancer cells through PD-1 receptor inhibition, thereby improving treatment outcomes and survival rates across various cancer types. For instance, in September 2025, according to the American Association for Cancer Research, a US-based professional organization, the number of new cancer cases diagnosed annually in the United States is projected to exceed 3.5 million by 2050, representing nearly a 40% increase from 2025 estimates. Therefore, rising cancer rates are driving the growth of the Zynyz market.

The growing geriatric population is expected to propel the growth of the Zynyz market. The geriatric population comprises individuals typically aged 65 and older, who often require specialized medical care due to age-related health challenges. The growth of this population is driven by increased life expectancy, improved healthcare, decreased fertility rates, better living standards, advances in medical technology, and societal support for elderly individuals. Zynyz benefits the geriatric population by providing targeted cancer therapies that improve survival rates and quality of life while minimizing side effects. For instance, in January 2024, according to the Population Reference Bureau (PRB), a US-based private non-profit organization, the U.S. population aged 65 and older is expected to grow by 47%, from 58 million in 2022 to 82 million by 2050, with their share of the total population rising from 17% to 23%. Therefore, a growing geriatric population drives the growth of the Zynyz market.

A key trend in the Zynyz market is the development of innovative products, such as monoclonal antibodies, to enhance targeted cancer therapies. Monoclonal antibodies are laboratory-produced molecules designed to bind specific cells or proteins, enabling precise treatment of cancers and autoimmune disorders. For instance, in March 2023, Incyte Corporation, a US-based pharmaceutical company, received FDA approval for Zynyz (retifanlimab-dlwr), a humanized monoclonal antibody targeting the PD-1 receptor, for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). This approval, granted under the FDA’s accelerated approval pathway, was based on positive tumor response rate and duration of response (DOR) data from clinical trials. The approval provides healthcare providers with a new first-line treatment option for MCC, a rare and aggressive skin cancer, offering hope to patients with limited existing therapies.

Major companies operating in the zynyz market are Incyte Corporation.

North America was the largest region in the zynyz market in 2025. The regions covered in the zynyz market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the zynyz market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the zynyz market by increasing costs of imported active pharmaceutical ingredients, specialized synthesis equipment, and formulation components used in targeted oncology drug production. Pharmaceutical manufacturers in North America and Europe are most affected due to reliance on imported intermediates, while Asia-Pacific faces cost pressure on export-oriented drug manufacturing. These tariffs raise production costs and affect drug pricing strategies. However, they are also encouraging domestic API manufacturing, regional drug synthesis capabilities, and supply chain diversification across oncology pharmaceuticals.

The zynyz market research report is one of a series of new reports that provides zynyz market statistics, including zynyz industry global market size, regional shares, competitors with a zynyz market share, detailed zynyz market segments, market trends and opportunities, and any further data you may need to thrive in the zynyz industry. This zynyz market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Zynyz (zotiraciclib) is a medication used to treat certain types of cancer. It is a targeted therapy that functions as a kinase inhibitor, interfering with cancer cell growth and survival by targeting specific proteins involved in the cancer cell cycle.

The primary indications for Zynyz are cancer and autoimmune diseases. Cancer comprises diseases in which abnormal cells grow uncontrollably, potentially forming tumors and spreading to other parts of the body. Zynyz is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, serving adult and elderly patients.

The zynyz market consists of sales of binimetinib tablets, combination therapies, supportive care products, companion diagnostics, and monoclonal antibodies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.